Results 101 to 110 of about 10,024 (235)

SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model

Nature Communications, 2022
Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned.
Carolin M. Lieber, Robert M. Cox, Julien Sourimant, Josef D. Wolf, Kate Juergens, Quynh Phung, Manohar T. Saindane, Meghan K. Smith, Zachary M. Sticher, Alexander A. Kalykhalov, Michael G. Natchus, George R. Painter, Kaori Sakamoto, Alexander L. Greninger, Richard K. Plemper   +14 more
doaj   +1 more source

Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Background Viral‐respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID‐19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma.
Mandana Akhavan, Parastoo Yousefi, Alireza Tabibzadeh   +2 more
wiley   +1 more source

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients

Clinical and Translational Science, 2022
The ongoing pandemic of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) and subsequently, coronavirus disease 2019 (COVID‐19), has led to the deaths of over 6.1 million people and sparked a greater interest in virology to expedite the ...
Raymond K. Hau, Stephen H. Wright, Nathan J. Cherrington   +2 more
doaj   +1 more source

Potential of Eugenia brejoensis (Mazine) Essential Oil in Combating Multidrug‐Resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa

Chemistry &Biodiversity, Volume 23, Issue 1, January 2026.
ABSTRACT The genus Eugenia has a long history of use in traditional medicine for treating various conditions, including infectious diseases, gastrointestinal disorders, and skin problems. Essential oils derived from Eugenia species are known for their medicinal properties and have been studied for their antimicrobial and bioactive potential. This study
Jonathan Mandú de Araújo, Amanda Vieira de Barros, Fábio Henrique Galdino Dos Santos, Weslley Felix De Oliveira, Daniela Maria do Amaral Ferraz Navarro, Márcia Vanusa da Silva, Bruno Oliveira de Veras, John Eversong Lucena de Vasconcelos, Henrique Douglas Melo Coutinho, Maria Betânia de Melo Oliveira, Maria Tereza dos Santos Correia   +10 more
wiley   +1 more source

Crystalline form of Molnupiravir and process for its preparation thereof [PDF]

, 2021
Crystalline form of ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate ...

core   +1 more source

Allosteric Inhibitors of SARS‐CoV‐2 RNA‐Dependent RNA Polymerase Based on N,N′‐Diphenylurea

ChemMedChem, Volume 21, Issue 1, January 2026.
Inhibitors of SARS‐CoV‐2 RdRp activity based on N,N′‐diphenylurea scaffold have been identified. Several compounds exhibit residual activity (RA) below 50% in an enzymatic assay (at 10 µM concentration) and improved aqueous solubility compared to the previously reported series of inhibitors.
Artem Chayka, Matěj Danda, Alžběta Dostálková, Vojtěch Spiwok, Lamija Zijadic, Anna Klimešová, Marina Kapisheva, Michala Zgarbová, Jan Weber, Tomáš Ruml, Michaela Rumlová, Zlatko Janeba   +11 more
wiley   +1 more source

Efficacy of Molnupiravir in Reducing the Risk of Severe Outcomes in Patients with SARS-CoV-2 Infection: A Real-Life Full-Matched Case–Control Study (SAVALO Study)

Microorganisms
We conducted a real-life case–control study among outpatients with Omicron SARS-CoV-2 infection to assess the effectiveness of molnupiravir (MNP) in reducing hospital admission, admission to the intensive care unit, and death at day 28.
Ivan Gentile, R. Scotto, Maria Michela Scirocco, Francesco Di Brizzi, F. Cuccurullo, M. Silvitelli, L. Ametrano, Francesco Antimo Alfè, D. Pietroluongo, Irene Irace, Mariarosaria Chiariello, Noemi De Felice, Simone Severino, G. Viceconte, Nicola Schiano Moriello, A. Maraolo, A. Buonomo, A. Giaccone, On Behalf Of Federico Ii Covid Team   +18 more
semanticscholar   +1 more source

Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics

MedComm, Volume 7, Issue 1, January 2026.
This review provides a comprehensive overview of the latest research advances in MPXV, with a focused analysis across five core dimensions: epidemiology, virology, diagnosis, vaccine, and therapeutics. The primary objective of this review is to advance the understanding of MPXV and facilitate the development of more effective diagnostic methods ...
Yunzheng Yan, Yaqin Sun, Guangyan Sun, Cheng Niu, Xinyuan Zhao, Ming Zhao, Tongyao Liu, Suyue Zhang, Hui Zhai, Ankang Liu, Shouzhi Yu, Shuyuan Pan, Wu Zhong, Yuntao Zhang, Song Li   +14 more
wiley   +1 more source

Molnupiravir or nirmatrelvir-ritonavir versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial [PDF]

Background: Molnupiravir and nirmatrelvir-ritonavir (Paxlovid) are oral antivirals that have been proposed as treatments for patients admitted to hospital with COVID-19.
Amuasi, John, Baillie, J Kenneth, Basnyat, Buddha, Buch, Maya H, Campbell, Mark, Chadwick, David, Cooke, Graham, Desai, Purav, Easom, Nicholas, Emberson, Jonathan R, Esmail, Hanif, Faust, Saul N, Ghosh, Dipansu, Hamers, Raph L, Hamilton, Fergus, Haynes, Richard, Hine, Paul, Horby, Peter W, Jaki, Thomas, Jeffery, Katherine, Juszczak, Edmund, Knight, Marian, Landray, Martin J, Lim, Wei Shen, Mafham, Marion, Majumdar, Jaydip, Montgomery, Alan, Mukherjee, Aparna, Mumford, Andrew, Nel, Jeremy, Pessoa-Amorim, Guilherme, Peto, Leon, RECOVERY Collaborative Group, Rowan, Kathryn, Sharp, Sara, Staplin, Natalie, Stewart, Richard, Thwaites, Catherine, Thwaites, Guy, Van Doorn, Hindrik   +39 more
core   +2 more sources